Trending

#convatec

Latest posts tagged with #convatec on Bluesky

Latest Top
Trending
#Illinois Primaries #Joe Kent #ICE Custody #St. Patrick's Day #World Baseball Classic #Rachel Maddow #Trump and Cuba #Vaccine Policy #DLSS 5 #Oscars #Illinois Primaries #Joe Kent #ICE Custody #St. Patrick's Day #World Baseball Classic #Rachel Maddow #Trump and Cuba #Vaccine Policy #DLSS 5 #Oscars

Posts tagged #convatec

Colostomy UK
Colostomy UK
@colostomyuk.bsky.social
4 months ago
Reflecting on the Convatec Healthy Bonds Webinar – October 22, 2025 An inspiring event bringing together stoma charities, healthcare professionals, and people with lived experience to share powerful insights on stoma care and cancer recovery. A special mention to Debbie Meredith for bravely sharing her journey and inspiring so many. Thank you Convatec, Dr. Tod Brindle, and Rob Grant for such a meaningful session and for the great resources through Convatec Academy.

Reflecting on the Convatec Healthy Bonds Webinar – October 22, 2025 An inspiring event bringing together stoma charities, healthcare professionals, and people with lived experience to share powerful insights on stoma care and cancer recovery. A special mention to Debbie Meredith for bravely sharing her journey and inspiring so many. Thank you Convatec, Dr. Tod Brindle, and Rob Grant for such a meaningful session and for the great resources through Convatec Academy.

Reflecting on the Convatec Healthy Bonds Webinar – October 22, 2025 An inspiring event bringing together stoma charities, healthcare professionals, and people with lived experience to share powerful insights on stoma care and cancer recovery. A special mention to Debbie Meredith for bravely sharing her journey and inspiring so many. Thank you Convatec, Dr. Tod Brindle, and Rob Grant for such a meaningful session and for the great resources through Convatec Academy.

Reflecting on the Convatec Healthy Bonds Webinar – October 22, 2025 An inspiring event bringing together stoma charities, healthcare professionals, and people with lived experience to share powerful insights on stoma care and cancer recovery. A special mention to Debbie Meredith for bravely sharing her journey and inspiring so many. Thank you Convatec, Dr. Tod Brindle, and Rob Grant for such a meaningful session and for the great resources through Convatec Academy.

Reflecting on the Convatec Healthy Bonds Webinar – October 22, 2025 An inspiring event bringing together stoma charities, healthcare professionals, and people with lived experience to share powerful insights on stoma care and cancer recovery. A special mention to Debbie Meredith for bravely sharing her journey and inspiring so many. Thank you Convatec, Dr. Tod Brindle, and Rob Grant for such a meaningful session and for the great resources through Convatec Academy.

Reflecting on the Convatec Healthy Bonds Webinar – October 22, 2025 An inspiring event bringing together stoma charities, healthcare professionals, and people with lived experience to share powerful insights on stoma care and cancer recovery. A special mention to Debbie Meredith for bravely sharing her journey and inspiring so many. Thank you Convatec, Dr. Tod Brindle, and Rob Grant for such a meaningful session and for the great resources through Convatec Academy.

Reflecting on the Convatec Healthy Bonds Webinar – October 22, 2025 An inspiring event bringing together stoma charities, healthcare professionals, and people with lived experience to share powerful insights on stoma care and cancer recovery. A special mention to Debbie Meredith for bravely sharing her journey and inspiring so many. Thank you Convatec, Dr. Tod Brindle, and Rob Grant for such a meaningful session and for the great resources through Convatec Academy.

Reflecting on the Convatec Healthy Bonds Webinar – October 22, 2025 An inspiring event bringing together stoma charities, healthcare professionals, and people with lived experience to share powerful insights on stoma care and cancer recovery. A special mention to Debbie Meredith for bravely sharing her journey and inspiring so many. Thank you Convatec, Dr. Tod Brindle, and Rob Grant for such a meaningful session and for the great resources through Convatec Academy.

Reflecting on the Convatec Healthy Bonds Webinar.

A brilliant session bringing together charities, clinicians & people with lived experience to share real stories and practical advice on stoma care and cancer recovery.

#StomaCare #CancerRecovery #Convatec #HealthyBonds #LivedExperience

0 0 0 0
Profit Trading USA
Profit Trading USA
@profittradingusa.bsky.social
6 months ago
RBC upgrades ConvaTec after $300 mln buyback, sets 315p target Investing.com -- ConvaTec Group Plc’s (LON:CTEC) rating has been upgraded to “outperform” from “sector perform” by RBC Capital Markets, with analysts setting a revised price target of 315p, down slightly from 320p. The change follows a 20% drop in the company’s shares since June, largely linked to concerns over proposed U.S. reimbursement changes. RBC analysts said the market reaction appears to have been “overdone,” pointing to underlying growth prospects and the company’s margin development in the medium term. The company has guided to a possible 1-2% revenue impact in 2026 from changes to U.S. reimbursement in Skin Substitutes, with an additional 1-2% hit in 2027 from the competitive bidding process in Ostomy and Continence Care. RBC estimates that the worst-case scenario could mean a low double-digit percentage impact on 2027 earnings per share, but noted that ConvaTec is likely to offset a meaningful portion of this through execution and cost management. RBC adjusted its forecasts following the company’s first-half results and incorporated the recently announced $300 million share buy-back program, which is expected to provide a low single-digit boost to EPS from 2025. Revenue forecasts for 2026 were increased by 1.3% due to stronger-than-expected performance in Infusion Care and favorable currency effects, though EPS was cut by 1.2% on expected margin dilution from Skin Substitute pricing changes. For 2027, revenue growth expectations were reduced by two percentage points to reflect a cautious outlook on chronic care reimbursement, implying a 3.4% earnings impact. The revised valuation applies a 20x P/E multiple to 2027 forecasts, down from 22x previously, to account for the added uncertainty in the U.S. reimbursement landscape. RBC said this still positions the stock attractively, given its current trading multiple of 16.5x 2026 estimated earnings, which is at the lower end of its five-year range and below its historical premium to peers. ConvaTec maintains mid-term guidance of 5-7% revenue compound annual growth and margins of 24-26% by 2027, which already factors in reimbursement pressures. RBC said this leaves room for potential upgrades if execution remains strong and reimbursement impacts are less severe than feared. Before you buy stock in CTEC, consider this: ProPicks AI are 6 easy-to-follow model portfolios created by Investing.com for building wealth by identifying winning stocks and letting them run. Over 150,000 paying members trust ProPicks to find new stocks to buy – driven by AI. The ProPicks AI algorithm has just identified the best stocks for investors to buy now. The stocks that made the cut could produce enormous returns in the coming years. Is CTEC one of them?

Click Subscribe #RBC #ConvaTec #Investing #StockMarket #Buyback

0 0 0 0
Straight Outta Cortisol
Straight Outta Cortisol
@silvawolves.bsky.social
7 months ago
Post image Post image Post image Post image

Ostomates! A new Center for Medicare/Medicaid rule could affect where you can get your supplies from. Submit a public comment against this at the link below.👇 👇 👇
#ostomy #ileosotomy #colostomy #urostomy #ostomate #convatec #CMS #Medicare #Medicaid #DHHS

www.federalregister.gov/documents/20...

1 0 0 0
Profit Trading USA
Profit Trading USA
@profittradingusa.bsky.social
7 months ago
Convatec CEO Karim Bitar takes medical leave, shares dip Investing.com -- Shares of British medical equipment maker Convatec Group (LON:CTEC) fell 1% on Monday after the company announced that CEO Karim Bitar will take a medical leave of absence. The company has appointed Jonny Mason, its current Chief Financial Officer, to serve as interim CEO during Bitar’s absence. In a related move, Convatec named Group Financial Controller Fiona Ryder as interim CFO to fill Mason’s position while he takes on the temporary leadership role. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Don't miss out on the next big opportunity! Stay ahead of the curve with ProPicks AI – 6 model portfolios fueled by AI stock picks with a stellar performance this year... In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech Stocks, and Mid Cap stocks, you can explore various wealth-building strategies. So if CTEC is on your watchlist, it could be very wise to know whether or not it made the ProPicks AI lists.

Click Subscribe #Convatec #KarimBitar #MedicalLeave #Stocks #Investing

0 0 0 0
Profit Trading USA
Profit Trading USA
@profittradingusa.bsky.social
9 months ago
RBC downgrades ConvaTec to “sector perform,” raises target to 320p Investing.com -- ConvaTec Group (LON:CTEC) was downgraded to "sector perform" from "outperform" by analysts at RBC Capital Markets, who said further share price gains are unlikely in the near term after a strong run of outperformance, in a note dated Monday. The brokerage raised its price target on the stock to 320p from 305p, reflecting upward revisions to its earnings forecasts. The downgrade comes as ConvaTec’s shares have surged about 30% relative to the broader sector since the beginning of 2025. Despite continued strong operational execution, RBC said the current valuation already reflects much of the recent positive developments, including momentum from the company’s InnovaMatrix portfolio and guidance upgrades. Analysts revised their earnings forecasts following the company’s four-month trading update. EPS estimates were raised by 1.2% for 2025 and 1.3% for 2026, reflecting improved margin expectations. RBC now projects ConvaTec will deliver a 14% compound annual EPS growth rate from 2025 to 2027. The updated 320p price target is based on applying a 22x multiple to the 2026 EPS forecast. RBC said this valuation places the stock in the upper half of its peer group range but leaves little room for additional multiple expansion in the short term. Risks cited include uncertainty around the performance of the InnovaMatrix unit, potential impacts from tariffs, and second-half margin execution. “Valuation is now at the upper end of the historical range and above the peer group average,” RBC analysts said. Longer-term, RBC maintains a more constructive view. If ConvaTec can maintain execution and achieve its target of mid-20s EBIT margins, RBC believes the stock could merit a higher P/E multiple. Under that scenario, a 24x multiple applied to 2027 forecasts would imply a share price of 400p by the end of 2026. Should you invest $2,000 in CTEC right now? ProPicks AI are 6 model portfolios created by Investing.com which identify the best stocks for investors to buy now. The stocks that made the cut could produce monster returns in the coming years. Is CTEC one of them?

Click Subscribe #RBC #ConvaTec #StockMarket #InvestmentNews #MarketAnalysis

0 0 0 0
Profit Trading USA
Profit Trading USA
@profittradingusa.bsky.social
11 months ago
Convatec outlook upgraded to positive by Moody’s Ratings Investing.com -- Moody’s Ratings has affirmed the Ba1 long-term corporate family rating (CFR) and Ba1-PD probability of default rating (PDR) of Convatec Group PLC, a UK-based global provider of chronic care products. In addition, the Ba1 backed senior unsecured rating of the $500 million notes due 2029 issued by 180 Medical Inc., a fully-owned operating subsidiary of Convatec, was also affirmed. The outlook for both entities has been upgraded to positive from stable. The rating affirmation and outlook upgrade are a result of solid organic revenue and margin growth backed by a successful transformation program and strong product pipeline, which exceeded the company’s 2024 guidance. Convatec’s focus on the chronic care market, which provides recurring revenue and supports strong long-term market growth expectations, also contributed to the rating actions. The company’s conservative financial policy, with a net leverage target of around 2x, and the expectation that Moody’s adjusted gross debt to EBITDA will be below 2.5x over the next 12-18 months, further supported the positive rating action. Convatec’s transformation program, which addressed historical operational and performance issues, has resulted in good organic growth over the past few years. The company’s focus on innovation and product mix, along with a strong pipeline of new product launches, are expected to support future organic growth and margin expansion. This is expected to improve credit metrics, with Moody’s adjusted debt/EBITDA below 2.5x over the next 12-18 months. The Ba1 CFR of Convatec is backed by its good scale and product diversification across multiple subsegments within chronic care. The company is well diversified geographically, but has less exposure to Asia. Convatec is a market leader in several product categories, which benefit from low demand cyclicality and stable annual market growth in the mid-single-digit percentage range. The company consistently generates positive free cash flow (FCF), which improved substantially in 2024 to $167 million from $29 million in 2022. However, the company faces credit constraints including social risks from downward pricing pressure as healthcare payors seek to control costs, potential product litigation risks, relatively lower margins compared to some competitors, and risks around the execution of the company’s product pipeline and expected efficiency gains. Convatec has good liquidity, with a cash balance of $65 million as of December 31, 2024, and $566.5 million equivalent availability under its $950 million revolving credit facility (RCF), supporting its liquidity position. The company’s $500 million backed senior unsecured notes issued by 180 Medical Inc. rank equally with the loan facilities which are also unsecured and benefit from equivalent guarantees across the group. Hence, the notes are rated in line with Convatec’s CFR at Ba1. The positive outlook reflects the expectation that Convatec will continue to grow its revenue in the mid-single digit percentage range and expand its margin while delivering on its productivity and simplification initiatives. The outlook also assumes that the company will maintain good liquidity. Upward rating pressure could occur if Convatec continues to enhance its scale and market positioning while growing its profit margins. An upgrade would also require Convatec to maintain conservative financial policies, including maintaining Moody’s adjusted gross debt/EBITDA around 2.0x. Downward pressure on the rating could develop if operating performance deteriorates, Moody’s adjusted gross debt/EBITDA increases above 3.0x, or a more aggressive financial policy is pursued, including not adhering to its stated leverage policy. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. CTEC: is this perennial leader facing new challenges? With valuations skyrocketing in 2024, many investors are uneasy putting more money into stocks. Sure, there are always opportunities in the stock market – but finding them feels more difficult now than a year ago. Unsure where to invest next? One of the best ways to discover new high-potential opportunities is to look at the top performing portfolios this year. ProPicks AI offers 6 model portfolios from Investing.com which identify the best stocks for investors to buy right now. For example, ProPicks AI found 9 overlooked stocks that jumped over 25% this year alone. The new stocks that made the monthly cut could yield enormous returns in the coming years. Is CTEC one of them?

Click Subscribe #Convatec #Moodys #StockMarket #Investing #FinancialNews

0 0 0 0
@adamcarolla90210.bsky.social
1 year ago
Preview
Happy exploring! It's okay to try a new system; it's also okay to stay close to what's comfortable. Regardless, if you have an issue with your ostomy, ask questions! I have no disclosures. @Convatec #... TikTok video by Nurse Ostomate

www.tiktok.com/t/ZT2Nbdokr/ #stoma #convatec

1 0 0 0